Video

Dr. Mesa on the Future of JAK Inhibitor Therapy in Myelofibrosis

Ruben A. Mesa, MD, discusses the future of JAK inhibitor therapy in myelofibrosis.

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the future of JAK inhibitor therapy in myelofibrosis.

The addition of more treatment options for myelofibrosis has been a benefit for patients and clinicians, Mesa says. Additionally, the FDA approval of a fourth JAK inhibitor, momelotinib, is anticipated in the near future, and it will bring its own distinct profile and complementary approach compared with other approved JAK inhibitors for myelofibrosis, Mesa explains.

In the long term, patients will be optimized on JAK inhibitor therapy based on characteristics, response, and dose, Mesa continues. An additional agent could also be implemented up-front or after a period of time, Mesa says.

More phase 3 trials in myelofibrosis are ongoing than ever before, and the outcomes of these studies will continue to help to guide treatment decisions, Mesa concludes.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP